MIRRI - updates on the progress of the establishment of the Microbial Resource Research Infrastructure


MIRRI is a pan-European distributed research infrastructure in its Preparatory Phase which aims to support research and development in the field of biotechnology. Issue 3 of  MIRRI newsletter provides updates on the progress of the establishment of the Microbial Resource Research Infrastructure.



Novel bicistronic cloning vector set based on P2A peptide


When expressing more than one gene in a cell line, often bicistronic expression vectors with an internal ribosomal entry site (IRES) are used. Instead of these large IRES sequences, a much shorter, self-cleaving 2A peptide (P2A) can be used. The efficient cleaving activity of this peptide was described in Kim et al. (2011; PMID: 21602908).

To make the advantages of the P2A peptide available for all scientists, BCCM/LMBP is proud to announce the bicistronic pEF6-P2A cloning vector.

Workshop on MALDI-TOF MS for the identification of Fungi


The 19th congress of the International Society of Human and Animal Mycology (ISHAM) will take place from the 4th until the 8th of May in Melbourne, Australia. BCCM/IHEM is involved in the organization of a workshop on MALDI-TOF MS for the identification of fungi, on the 3th of May. More information can be found here:

We are hoping to welcome you in Melbourne!

Human ORFeome v8.1 - find your gene in a Gateway Entry vector at LMBP


The hORFv8.1 library consists of a sequence-verified, clonal collection of human Open Reading Frames (ORFs), presented as individual Gateway Entry vectors (backbone: pDONR223). 

The new BCCM/LMBP search engine makes the quest for your gene of interest easy, with a database containing, among others, all names and symbols ever assigned to it.

All clones come without a termination codon, allowing the addition of C-terminal tags or markers.

Bedaquiline- and clofazimine-resistant Mycobacterium tuberuclosis reference strains available in public collection of mycobacterial strains BCCM/ITM


The global burden of multi-drug tuberculosis (MDR-TB) was estimated  in 2013 at  5.3% of TB cases, including  9% with extensively drug-resistant tuberculosis (XDR-TB)1.  Only 48% of MDR cases were treated successfully, in part due to high toxicity, the long duration of the current regimens, and drug supply interruptions. To overcome these constraints, new TB drugs were deemed essential  and have been  developed, yet their safety and efficacy are being assessed in Phase II and III clinical trials for patients with MDR-TB.

Biological control agents: from field to market, problems, and challenges


New publication by Siva L.S. Velivelli, Paul De Vos, Peter Kromann,Stephane Declerck, Barbara D. Prestwich in Trends in Biotechnology

This article focuses on the problems and challenges encountered when introducing biological control agents on the market. The role that culture collections, such as the BCCM collections, can play in this process is described.


BCCM/IHEM organises a course on fungi of the environment from 29 September until 3 October 2014


From the 29th of September until the 3th of October, training in Mycology is organised at BCCM/IHEM. This one week training is focusing on Fungi of the human environment and includes a theoretical part as well as practical training in the laboratory.

Interested in such a training? Need more details?
Please contact us at